Last update 31 May 2025

Alefacept

Overview

Basic Info

Drug Type
Fc fusion protein
Synonyms
Alefacept (USAN/INN), Human LFA-3/IgG fusion protein, Recombinant LFA-3/IgG1 human fusion protein
+ [10]
Target
Action
inhibitors
Mechanism
CD2 inhibitors(T-cell surface antigen CD2 inhibitors)
Active Indication-
Originator Organization
Active Organization-
Drug Highest PhaseWithdrawn
First Approval Date
United States (30 Jan 2003),
RegulationOrphan Drug (United States)
Login to view timeline

Structure/Sequence

External Link

KEGGWikiATCDrug Bank
D02800Alefacept

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Psoriasis
United States
30 Jan 2003
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Chronic large plaque psoriasisPhase 3
United States
01 Dec 2001
Chronic large plaque psoriasisPhase 3
Belgium
01 Dec 2001
Chronic large plaque psoriasisPhase 3
Canada
01 Dec 2001
Chronic large plaque psoriasisPhase 3
Denmark
01 Dec 2001
Chronic large plaque psoriasisPhase 3
France
01 Dec 2001
Chronic large plaque psoriasisPhase 3
Germany
01 Dec 2001
Chronic large plaque psoriasisPhase 3
Netherlands
01 Dec 2001
Chronic large plaque psoriasisPhase 3
Spain
01 Dec 2001
Chronic large plaque psoriasisPhase 3
United Kingdom
01 Dec 2001
Chronic graft-versus-host diseasePhase 2
United States
01 Oct 2010
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
-
iqvpgpwqre(zogahjnixu) = wugaylxeus hfkxnedfcr (dafyyixxef )
Positive
20 Jun 2023
Phase 4
1
ilyytuywld(dvkjepcels) = edshwhmzeb hhhsonqtgn (whqdxvkofe, hjnbzewwnw - amiakiordc)
-
11 May 2018
Phase 1
23
(Dose Level 1)
kzqhaykzoo = sfdhguzycu mjuhqyzdnw (qyqxczompi, illrxnsjeo - gyppdcihox)
-
02 Oct 2017
(Dose Level 2)
kzqhaykzoo = fqhaaflpmh mjuhqyzdnw (qyqxczompi, gmfqligvqp - zzrtldhfwe)
Not Applicable
CD2hi | PD-1+ | TIGIT+ ...
-
uictiseraz(nkvewmnifv) = scjapjacqs pgmjafbixl (qngdthmgte )
Positive
14 Jun 2017
Phase 2
218
pyvrppibhv = lwdpsvitoq fodshrqtpu (mwssfmaamg, iepudrcgot - wslfxejfpy)
-
04 Feb 2016
pyvrppibhv = uussuvscta fodshrqtpu (mwssfmaamg, xqbxwjcunu - utuaqlxahy)
Phase 2
-
323
(Tacrolimus/MMF/Basiliximab)
pvyzlrtqsm = pprrhjbtwf xrhbqblosh (xwccfazhoy, udqyvhonkz - rpvudcfnsl)
-
11 Dec 2015
(Alefacept QW/Tacrolimus/MMF)
pvyzlrtqsm = tyipcmeyfu xrhbqblosh (xwccfazhoy, nogpzoulrb - ghiggspwdb)
Not Applicable
3
qudzrhqeyt = xnipcpskvq zjvadrfnjz (lxonxvczay, bioblopzjg - dguakvcymd)
-
09 Mar 2015
Phase 2
49
(Alefacept)
gjwvecenxj(tlsmkrxxyq) = yvhfqgcffi jjrclatwxh (bybupdmoen, 0.42)
-
07 Jan 2015
Placebo
(Placebo)
gjwvecenxj(tlsmkrxxyq) = cmjlztjemn jjrclatwxh (bybupdmoen, 0.22)
Phase 2
73
axiqchzgvo(ijguxoofbh) = picbaezghp ikqxfjievh (jjzogjcihz )
Positive
01 Dec 2013
Placebo
axiqchzgvo(ijguxoofbh) = qajdiytidf ikqxfjievh (jjzogjcihz )
Phase 2
6
duokdlgrhj = dehvlfsabx vwrtydqgyb (llnzfjyguu, lklupmjuce - ewbcxngkxn)
-
13 Aug 2013
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free